OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)

Clinical trial NCT01916785 · COMPLETED

Trial details

NCT number: NCT01916785
Sponsor: Versailles Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Myelogenous Leukemia, BCR/ABL Positive

Start date: 2009-05-01
Primary completion: 2013-12-01
Enrollment: 289

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.